|
Market Cap (25-Jun) $125,067,280 (1,258th) |
Close (30-Jun) $0.007 |
Volume (30-Jun) 188,484 |
Shortsold (14-May) 14,985,846 (0.14%) (426th) |
|
52w High $0.85 |
52w Low $0.350 |
P/E 10.33 |
EPS -0.07 |
ATH released this announcement to the ASX on 23 June 2022, 9:16. The announcement is marked as price sensitive, and is 3 page(s) in length and 201.49kb in size.
You can view all announcements from ATH and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATH was 0.001% short sold according to ASIC data. It was ranked the 636th most shorted stock on the ASX. It is now ranked as the 426th most shorted stock on the ASX with 0.138% of total shares short sold as of the latest reported data (14 May 2026).
| Other Recent Announcements from ATH | |
|---|---|
| Investor Presentation | 22 June 2023, 11:13 |
| ATH to present at MST Rare Diseases Rich Returns Forum | 21 June 2023, 9:52 |
| ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder | 30 May 2023, 13:32 |
| Regulatory Approval to Proceed with Phase 2 Trial in Italy | 23 June 2022, 9:16 |
| Alterity to Present at Life Sciences Investor Forum | 20 June 2022, 9:04 |
| Alterity to present at GCFF Virtual Conference 2022 | 14 June 2022, 14:33 |
| Alterity Launches ATH434 Phase 2 Clinical Trial | 2 June 2022, 9:59 |
You must be logged in to post a reply.
Alterity Therapeutics 